Coverage
The Merck Access Program for VERQUVO® (vericiguat) may be able to help answer questions about insurance coverage for patients, benefit investigations, and the prior authorization and appeals process.
The Merck Access Program for VERQUVO® (vericiguat) may be able to help answer questions about insurance coverage for patients, benefit investigations, and the prior authorization and appeals process.
VERQUVO is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
WARNING: EMBRYO-FETAL TOXICITY
Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.
Before prescribing VERQUVO, please read the accompanying Prescribing information including the Boxed Warning about embryo-fetal toxicity. The Medication guide also is available.
VERQUVO is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
VERQUVO is indicated to reduce the risk of cardiovascular death and heart
VERQUVO is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.